Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totaling 112,316 shares, a decrease of 77.6% from the April 15th total of 502,390 shares. Based on an average trading volume of 169,623 shares, the short-interest ratio is currently 0.7 days. Approximately 2.6% of the company’s stock are sold short.

Galmed Pharmaceuticals Price Performance

Shares of Galmed Pharmaceuticals stock traded down $0.06 during trading on Friday, hitting $0.60. 110,127 shares of the company’s stock traded hands, compared to its average volume of 2,062,700. Galmed Pharmaceuticals has a 1 year low of $0.41 and a 1 year high of $2.34. The stock has a market capitalization of $3.29 million, a P/E ratio of -0.48 and a beta of 0.62. The business has a 50-day simple moving average of $0.62 and a 200-day simple moving average of $0.79.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Citadel Advisors LLC acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 3.05% of Galmed Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.